Gara Jalqabaatti › Myelodysplastic Syndromes › Massachusetts › Boston
Qorannoo klinikaalii Myelodysplastic Syndromes Boston, MA keessatti
Qorannoo 19 Myelodysplastic Syndromes f Boston fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Tufts Medical Center, Boston
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Namoota walitti qabaa jiraSadarkaa 1
- Dana-Farber Cancer Institute, Boston
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Dana-Farber Cancer Institute, Boston
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Namoota walitti qabaa jiraSadarkaa 3
- Massachusetts General Hospital, Boston
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Namoota walitti qabaa jiraSadarkaa 1/2
- Dana-Farber Cancer Institute, Boston
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Namoota walitti qabaa jiraSadarkaa 1Hojjettoota fayyaa simatamoo
- Brigham and Women's Hospital, Boston
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Namoota walitti qabaa jiraSadarkaa 1
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Namoota walitti qabaa jiraSadarkaa 1
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Namoota walitti qabaa jiraSadarkaa 1
- Dana Farber Cancer Institute, Boston
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Namoota walitti qabaa jiraQorannoo ilaalaa
- Dana-Farber Cancer Institute, Boston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Namoota walitti qabaa jiraSadarkaa 2/3
- Dana-Farber Cancer Institute, Boston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- Dana-Farber Cancer Institute, Boston
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Namoota walitti qabaa jiraSadarkaa 2Hojjettoota fayyaa simatamoo
- DFCI/BWH Brigham and Women's Hospital, Boston
IS-free Treg HaploHCT
Namoota walitti qabaa jiraSadarkaa 1
- Dana Farber Cancer Institute, Boston
HEME Home Transfusion Program
Namoota walitti qabaa jira
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Study of REM-422 in Patients With AML or Higher Risk MDS
Namoota walitti qabaa jiraSadarkaa 1
- Massachusetts General Hospital, Boston
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Namoota walitti qabaa jiraSadarkaa 1
- Dana-Farber Cancer Institute, Boston
Qorannoo Myelodysplastic Syndromes magaalota biroo keessatti
- Houston, TXQorannoo 43
- Baldwin Park, CAQorannoo 26
- New York City, NYQorannoo 21
- Seattle, WAQorannoo 21
- Washington, DCQorannoo 20
- Tampa, FLQorannoo 19
- Miami, FLQorannoo 17
- Durham, NCQorannoo 14
- Columbus, OHQorannoo 14
- St. Louis, MOQorannoo 13
- Atlanta, GAQorannoo 13
- Chicago, ILQorannoo 13
Qorannoo biroo Boston keessatti
- Saree OljooQorannoo 112
- Kansara Qara'a Non-Small CellQorannoo 90
- Saree (Gosoota Hunda)Qorannoo 85
- Kansara MetastatikiiQorannoo 63
- Kansarii ColorectalQorannoo 63
- Dhibee QaraQorannoo 62
- Kansarii OvariiQorannoo 61
- Kansarii ProstateQorannoo 59
- DepreshiniiQorannoo 52
- Kansa EndometiriyaaliiQorannoo 50
- Cufama OnneeQorannoo 44
- Leukemia Myeloidii HamaaQorannoo 44
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.